In vivo antitumor activity of neocarzinostatin (NCS)-tumor antibody conjugate against a transplantable human leukemia cell line (BALL-1).
The in vivo antitumor activity of NCS-immune immunoglobulin G (IgG) [Neocarzinostatin (NCS) conjugated with rabbit IgG antibody against a human leukemia cell line (NALL-1)] was evaluated in immunosuppressed newborn Syrian hamsters into which a transplantable human leukemia cell line, BALL-1 was implanted. After intraperitoneal (i.p.) injection of the conjugate, hamsters preinoculated i.p. with BALL-1 cells survived longer than hamsters treated with control solutions (p less than 0.01). The control solutions were NCS, immune IgG, a mixture of NCS and immune IgG, NCS-normal IgG conjugate and physiological saline. There was no change in body weight in the NCS-immune IgG-treated hamsters. The growth of subcutaneously (s.c.) implanted BALL-1 tumors was also inhibited by i.p. administration of NCS-immune IgG; however, the degree of inhibition was not significantly different from that obtained by administration of NCS alone, a mixture of NCS and immune IgG or NCS-normal IgG conjugate. These results indicate that NCS-immune IgG was effective against i.p. BALL-1 tumors, but was less effective against s.c. implanted tumors.
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage*; D000912:Antibodies, Neoplasm / Q000008:administration & dosage*; D002460:Cell Line; D006224:Cricetinae; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage*; D007942:Leukemia, Experimental / Q000188:drug therapy / Q000276:immunology; D007945:Leukemia, Lymphoid / Q000188:drug therapy* / Q000276:immunology; D008647:Mesocricetus; D009368:Neoplasm Transplantation; D009353:Zinostatin / Q000008:administration & dosage*
D000903:Antibiotics, Antineoplastic; D000912:Antibodies, Neoplasm; D007074:Immunoglobulin G; D009353:Zinostatin